Sana Biotechnology Statistics
Total Valuation
SANA has a market cap or net worth of $854.71 million. The enterprise value is $836.21 million.
| Market Cap | 854.71M |
| Enterprise Value | 836.21M |
Important Dates
The last earnings date was Monday, May 11, 2026, after market close.
| Earnings Date | May 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
SANA has 299.90 million shares outstanding. The number of shares has increased by 11.48% in one year.
| Current Share Class | 299.90M |
| Shares Outstanding | 299.90M |
| Shares Change (YoY) | +11.48% |
| Shares Change (QoQ) | +0.35% |
| Owned by Insiders (%) | 6.26% |
| Owned by Institutions (%) | 46.51% |
| Float | 191.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 6.45 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.29, with a Debt / Equity ratio of 0.69.
| Current Ratio | 1.29 |
| Quick Ratio | 1.17 |
| Debt / Equity | 0.69 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -147.41% and return on invested capital (ROIC) is -44.81%.
| Return on Equity (ROE) | -147.41% |
| Return on Assets (ROA) | -27.48% |
| Return on Invested Capital (ROIC) | -44.81% |
| Return on Capital Employed (ROCE) | -62.67% |
| Weighted Average Cost of Capital (WACC) | 14.70% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.70M |
| Employee Count | 142 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +10.04% in the last 52 weeks. The beta is 2.16, so SANA's price volatility has been higher than the market average.
| Beta (5Y) | 2.16 |
| 52-Week Price Change | +10.04% |
| 50-Day Moving Average | 3.22 |
| 200-Day Moving Average | 3.83 |
| Relative Strength Index (RSI) | 42.68 |
| Average Volume (20 Days) | 3,751,859 |
Short Selling Information
The latest short interest is 39.33 million, so 13.11% of the outstanding shares have been sold short.
| Short Interest | 39.33M |
| Short Previous Month | 38.47M |
| Short % of Shares Out | 13.11% |
| Short % of Float | 20.54% |
| Short Ratio (days to cover) | 9.49 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -180.06M |
| Pretax Income | -241.99M |
| Net Income | -241.99M |
| EBITDA | -168.57M |
| EBIT | -180.06M |
| Earnings Per Share (EPS) | -$0.92 |
Balance Sheet
The company has $101.14 million in cash and $82.63 million in debt, with a net cash position of $18.51 million or $0.06 per share.
| Cash & Cash Equivalents | 101.14M |
| Total Debt | 82.63M |
| Net Cash | 18.51M |
| Net Cash Per Share | $0.06 |
| Equity (Book Value) | 119.24M |
| Book Value Per Share | 0.44 |
| Working Capital | 25.43M |
Cash Flow
In the last 12 months, operating cash flow was -$132.55 million and capital expenditures -$1.09 million, giving a free cash flow of -$133.64 million.
| Operating Cash Flow | -132.55M |
| Capital Expenditures | -1.09M |
| Depreciation & Amortization | 11.49M |
| Net Borrowing | -353,000 |
| Free Cash Flow | -133.64M |
| FCF Per Share | -$0.45 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
SANA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.48% |
| Shareholder Yield | -11.48% |
| Earnings Yield | -28.31% |
| FCF Yield | -15.64% |
Analyst Forecast
The average price target for SANA is $8.57, which is 200.70% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.57 |
| Price Target Difference | 200.70% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |